Analysis of the immunohistochemical expressions of p53, bcl-2 and Ki-67 in colorectal adenocarcinoma and their correlations with the prognostic factors

Arquivos de Gastroenterologia

Volumn 47, Issue 2, 2010, Pages 141-147

  De Menezes, Hunaldo Lima ^a   Jucá, Mário Jorge ^b   Gomes, Edmundo Guilherme De A ^b   Nunes, Benício L Bulhões B P ^a   Costa, Henrique Oliveira ^c   Matos, Delcio ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF ALAGOAS   (Brazil)

^c UNIVERSIDADE ESTADUAL DE CIÊNCIAS DA SAÚDE DE ALAGOAS   (Brazil)

Author keywords

Adenocarcinoma; Bcl 2 homologous antagonist killer protein; Colorectal neoplasms; Immunohistochemistry; Proto oncogene proteins c bcl 2; Tumor suppressor protein p53

Indexed keywords

KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BRAZIL; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL DIFFERENTIATION; COLORECTAL CARCINOMA; CORRELATION ANALYSIS; DISEASE FREE INTERVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77957299845     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/S0004-28032010000200005     Document Type: Article

References (32)

1. Allegra CJ, Paik S, Colangelo LH, Parr AL, Kirsch I, Kim G, Klein P, Johnston PG, Wolmark N, Wieand HS. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol. 2003;21:241-50. (Pubitemid 46606152)
2. Bendardaf R, Ristamaki R, Kujari H, Laine J, Lamlum H, Collan Y, Pyrhonen S. Apoptotic index and bcl-2 expression as prognostic factors in colorectal carcinoma. Oncology. 2003;64:435-42.
3. Bishnupuri KS, Luo Q, Murmu N, Houchen CW, Anant S, Dieckgraefe BK. Reg IV activates the epidermal growth factor receptor/Akt/AP-1 signaling pathway in colon adenocarcinomas. Gastroenterology. 2006;130:137-49.
4. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer. 2000;88:1739-57.
5. Costa HO. Imunoexpressão das proteínas da família bcl-2 em carcinomas colorretais e sua correlação com índice apoptótico, proliferação celular e sobrevida [tese]. São Paulo: Universidade Federal de São Paulo; 2008.
6. Fernandes LC, Matos D. Marcadores tumorais no câncer colorretal. Rev Col Bras Cir. 2002;29:106-11.
7. Forones NM, Oshima C, Nanogaki S, Tanaka M, Barbosa V. Determinação da atividade proliferativa pelo Ki-67 e p53 em doentes com câncer colorretal. Arq. gastroenterol. 1999;36:122-6.
8. Galizia G, Ferraraccio F, Lieto E, Orditura M, Castellano P, Imperatore V, Romano C, Vollaro M, Agostini B, Pignatelli C, De Vita F. Prognostic value of p27, p53, and vascular endothelial growth factor in Dukes A and B colon cancer patients undergoing potentially curative surgery. Dis Colon Rectum. 2004;47:1904-14. (Pubitemid 40064435)
9. Garrity MM, Burgart LJ, Mahoney MR, Windschitl HE, Salim M, Wiesenfeld M, Krook JE, Michalak JC, Goldberg RM, O'Connell MJ, Furth AF, Sargent DJ, Murphy LM, Hill E, Riehle DL, Meyers CH, Witzig TE. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol. 2004;22:1572-82.
10. Gomes EGA. Análise das expressões imunohistoquímicas da metaloproteinase-1, metaloproteinase-7 e do fator de crescimento endotelial vascular no adenocarcinoma colorretal e suas correlações com os fatores prognósticos [tese]. São Paulo: Universidade Federal de São Paulo; 2008.
11. Grivicich I, Regner A, Rocha AB. Morte celular por apoptose. Rev Bras Cancerol. 2007;53:335-43.
12. Hashimoto Y, Skacel M, Lavery IC, Mukherjee AL, Casey G, Adams JC. Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas. BMC Cancer. 2006;6:241.
13. Instituto Nacional do Câncer. Estimativa 2008 - incidência de câncer no Brasil. Rio de Janeiro; 2008 [citado 2008 aug 24]. Disponível em: http://www.inca.gov.br/estimativa/2008/topo.asp.
14. Ishidaa H, Miwab H, Tatsutaa M, Masutania S, Imamuraa H, Shimizua J, Ezumia K, Katoa H, Kawasakia T, Furukawaa H, Kawakami H. Ki-67 and CEA expression as prognostic markers in Dukes' C colorectal cancer. Cancer Lett. 2004;207:109-15. (Pubitemid 38429893)
15. Jucá, M, Nunes BLBBP, Menezes HL, Gomes EGA, Matos D. Metaloproteinases 1 e 7 e câncer colorretal. Rev Bras Coloproctol. 2008;28:353-62.
16. Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N, Allegra CJ. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol. 2007;25:767-72.
17. Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna SN, Mukherjee R, Tam L, Munro AF, Dunne B, Bartlett JMS. Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology. 2006;48: 787-94.
18. Lima JM, Serafim PVP, Silva IDCG, Forones NM. Estudo do polimorfismo genético no gene p53 (códon 72) em câncer colorretal. Arq Gastroenterol. 2006;43: 8-13.
19. Lustosa SAS, Logullo A, Artigiani R, Saad SS, Goldenberg A, Matos D. Analysis of the correlation between p53 and bcl-2 expression with staging and prognosis of the colorectal adenocarcinoma. Acta Cir Bras. 2005;20:353-7.
20. Nehls O, Okech T, Hsieh CJ, Enzinger T, Sarbia M, Borchard F, Gruenagel HH, Gaco V, Hass HG, ArkenauHT, Hartmann JT, Porschen R, Grego M, Klump B. Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemoterapy: major prognostic impact of proapoptotic BAX. Br J Cancer. 2007; 96:1409-18.
21. Oshima CT, Iriya K, Forones NM. Ki 67 as a prognostic marker in colorectal cancer but not in gastric cancer. Neoplasma. 2005;52:420-4. (Pubitemid 41406691)
22. Paluszkiewicz P, Berbec H, Wakowicz BP, Cybulski M, Paszkowska A. p53 protein accumulation in colorectal cancer tissue has prognostic value only in left-sided colon tumours. Cancer Detec Prev. 2004;28:252-9.
23. Pereira H, Silva S, Julião R, Garcia P, Perpétua F. Prognostic markers for colorectal cancer: expression of p53 and bcl-2. World J Surg. 1997;21:210-3.
24. Resnick MB, Routhier J, Konkin T, Sabo E, Pricolo VE. Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res. 2004;10: 3069-75. (Pubitemid 38619685)
25. Ribeiro Jr U, Alves VA, Souza PMSB, Ribeiro AVS, Rawet V, Nonogaki S, Rodrigues JG, Habr-Gama A. Correlação das proteínas p53 e Ki67 com o prognóstico de pacientes com adenocarcinoma do reto distal. Rev Bras Coloproctol. 2000;20:248-56.
26. Rocha FTR, Lourenço LG, Jucá MJ, Leal AT, Paz AMDC. Expressão da proteína p53 no adenocarcinoma gástrico: correlação clínica, anatomopatológica e significância prognóstica. Rev Col Bras Cir. 2004;31:186-93.
27. Saleh HA, Jackson H, Banerjee M. Immunohistochemical expression of bcl-2 and p53 oncoproteins: correlation with Ki67 proliferation index and prognostic histopathologic parameters in colorectal neoplasia. Appl Immunohistochem Mol Morphol. 2000;8:175-82.
28. Schwandner O, Schlamp A, Broll R, Bruch HP. Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer. Int J Colorectal Dis. 2007;22:127-36.
29. Xi Y, Shalgi R, Fodstad O, Pilpel Y, Ju J. Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. Clin Cancer Res. 2006;12:2014-24.
30. Zavrides H, Zizi-Sermpetzoglou A, Elemenoglou I, Papatheofanis I, Peros G, Athanasas G, Panousopoulos D. Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance. Pol J Pathol. 2006;57:149-59.
31. Zhao DP, Ding XW, Peng JP, Zheng YX, Zhang SZ. Prognostic significance of bcl-2 and p53 expression in colorectal carcinoma. J Zheijiang Univ Sci. 2005;6:1163-9.
32. Zlobec I, Steele R, Michel RP, Compton CC, Lugli A, Jass JR. Scoring of p53, VEGF, Bcl-2 and APAF-1 immunohistochemistry and interobserver reliability in colorectal cancer. Mod Pathol. 2006;19:1236-42.